|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November, 2019
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mrs S Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
The sale of 1,158 Ordinary Shares, at a price of £17.2835
pursuant to a transfer into an ISA.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.2835
|
1,158
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-11-08
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mrs S Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
The repurchase of 1,149 Ordinary Shares, at a price of
£17.2937, to implement a transfer into an ISA.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.2937
|
1,149
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-11-08
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D Jackson
|
|
b)
|
Position/status
|
PCA of Mrs S Jackson (SVP, Global Communications & CEO
Office)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
The sale of 1,158 Ordinary Shares at a price of £17.2935
pursuant to a transfer into an ISA.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.2935
|
1,158
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-11-08
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D Jackson
|
|
b)
|
Position/status
|
PCA of Mrs S Jackson (SVP, Global Communications & CEO
Office)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the transaction
|
The repurchase of 1,150 Ordinary Shares at a price of £17.2905
to implement a transfer into an ISA.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£17.2905
|
1,150
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-11-08
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
08, 2019
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
| 
